XNAS · Healthcare · Biotechnology
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | 0.06 | 0.07 | +16.67% | $31.5M | ✅ Beat | -7.85% | -24.35% | — |
| 2026-03-04 | Q4 2025 | 0.01 | 0.03 | +200.00% | $33.8M | ✅ Beat | +18.41% | -1.01% | -11.34% |
| 2025-11-04 |
| Q3 2025 |
| 0.01 |
| 0.05 |
| +400.00% |
| $34.0M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | 0.01 | 0.04 | +300.00% | $31.1M | ✅ Beat | +25.00% | +7.66% | +0.11% |
| 2025-03-04 | Q4 2024 | 0.02 | 0.09 | +350.00% | $29.1M | ✅ Beat | — | — | -14.34% |
| 2024-10-31 | Q3 2024 | 0.00 | 0.02 | +100.00% | $25.6M | ✅ Beat | — | — | — |
| 2024-08-07 | Q2 2024 | -0.02 | 0.00 | +100.00% | $22.7M | ✅ Beat | — | — | — |
| 2024-05-08 | Q1 2024 | -0.02 | -0.01 | +50.00% | $22.2M | ✅ Beat | — | — | — |
Showing last 8 quarters.